897 related articles for article (PubMed ID: 9293187)
41. Quinolone mode of action--new aspects.
Hooper DC
Drugs; 1993; 45 Suppl 3():8-14. PubMed ID: 7689456
[TBL] [Abstract][Full Text] [Related]
42. A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
Gruger T; Nitiss JL; Maxwell A; Zechiedrich EL; Heisig P; Seeber S; Pommier Y; Strumberg D
Antimicrob Agents Chemother; 2004 Dec; 48(12):4495-504. PubMed ID: 15561817
[TBL] [Abstract][Full Text] [Related]
43. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
[TBL] [Abstract][Full Text] [Related]
44. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
45. Decatenating activity of Escherichia coli DNA gyrase and topoisomerases I and III during oriC and pBR322 DNA replication in vitro.
Hiasa H; DiGate RJ; Marians KJ
J Biol Chem; 1994 Jan; 269(3):2093-9. PubMed ID: 8294462
[TBL] [Abstract][Full Text] [Related]
46. Cell killing by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes.
Bernard P; Couturier M
J Mol Biol; 1992 Aug; 226(3):735-45. PubMed ID: 1324324
[TBL] [Abstract][Full Text] [Related]
47. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
48. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials.
Khodursky AB; Cozzarelli NR
J Biol Chem; 1998 Oct; 273(42):27668-77. PubMed ID: 9765303
[TBL] [Abstract][Full Text] [Related]
49. [Mechanisms for the development of quinolone resistance].
Kojima M
Nihon Rinsho; 1997 May; 55(5):1252-60. PubMed ID: 9155183
[TBL] [Abstract][Full Text] [Related]
50. Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA.
Aedo S; Tse-Dinh YC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5458-64. PubMed ID: 22869559
[TBL] [Abstract][Full Text] [Related]
51. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
52. Mechanism of quinolone action and resistance.
Aldred KJ; Kerns RJ; Osheroff N
Biochemistry; 2014 Mar; 53(10):1565-74. PubMed ID: 24576155
[TBL] [Abstract][Full Text] [Related]
53. New Escherichia coli gyrA and gyrB mutations which have a graded effect on DNA supercoiling.
Aleixandre V; Urios A; Herrera G; Blanco M
Mol Gen Genet; 1989 Oct; 219(1-2):306-12. PubMed ID: 2559316
[TBL] [Abstract][Full Text] [Related]
54. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
55. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.
Yamagishi J; Kojima T; Oyamada Y; Fujimoto K; Hattori H; Nakamura S; Inoue M
Antimicrob Agents Chemother; 1996 May; 40(5):1157-63. PubMed ID: 8723458
[TBL] [Abstract][Full Text] [Related]
56. Quinolone mode of action.
Hooper DC
Drugs; 1995; 49 Suppl 2():10-5. PubMed ID: 8549276
[TBL] [Abstract][Full Text] [Related]
57. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.
Fournier B; Zhao X; Lu T; Drlica K; Hooper DC
Antimicrob Agents Chemother; 2000 Aug; 44(8):2160-5. PubMed ID: 10898691
[TBL] [Abstract][Full Text] [Related]
58. Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.
Akasaka T; Onodera Y; Tanaka M; Sato K
Antimicrob Agents Chemother; 1999 Mar; 43(3):530-6. PubMed ID: 10049263
[TBL] [Abstract][Full Text] [Related]
59. Topoisomerase IV can support oriC DNA replication in vitro.
Hiasa H; Marians KJ
J Biol Chem; 1994 Jun; 269(23):16371-5. PubMed ID: 8206945
[TBL] [Abstract][Full Text] [Related]
60. Distinct effects of the UvrD helicase on topoisomerase-quinolone-DNA ternary complexes.
Shea ME; Hiasa H
J Biol Chem; 2000 May; 275(19):14649-58. PubMed ID: 10799552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
